EXTON, Pa., July 16, 2004 -- ViroPharma Incorporated (Nasdaq:VPHM) announced today that the company will host a 'Teach-in' on cytomegalovirus (CMV) infection at the Plaza Hotel in New York City at 5:00 P.M. Eastern Time on July 21, 2004. At the meeting, transplant physicians and members of senior management will provide an overview of CMV in the immunocompromised and transplant setting, the challenges of managing patients at risk of CMV infection, currently available treatments, the opportunities for new therapies, and an overview of maribavir, ViroPharma's leading clinical candidate molecule that inhibits CMV.